Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

Phase 3

Completed

Brief Summary: The purpose of this study is to assess if aprotinin (BAY A0128), given intravenously during surgery, is safe and can help reduce the amount of bleeding and the need for a blood transfusion during hip replacement surgery. Patients undergoing major surgery are at risk for significant blood loss. Because of this, there is a need for drugs that will help slow the amount of bleeding during surgery.

Recruitment & Eligibility

Inclusion Criteria

Subjects requiring elective primary total hip replacement surgery
Documented, signed, dated informed consent obtained prior to any study specific procedures being performed

Exclusion Criteria

Subjects with previous exposure to aprotinin in the last 6 months. If the subject has undergone cardiac surgery in the last 6 months, all attempts should be made to ascertain if aprotinin was administered during cardiac surgery. If no records are available, subject should be excluded. If during cardiac surgery in the last 6 months, there is a record of aprotinin administration, subject should be excluded
Subjects with a known or suspected allergy to aprotinin - Subjects with impaired renal function (serum creatinine > 3.5 mg/dl or 309 micromoles/liter)
Subjects with a history of bleeding diathesis or known coagulation factor deficiency
Subjects with failure of a major organ system or any active significant medical illness that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
Subjects who refuse to receive allogenic blood products for religious or other reasons

Arm && Interventions

Group	Intervention	Description
Arm 1	Trasylol (Aprotinin, BAYA0128)	-
Arm 2	Placebo	-

Primary Outcome Measures

Name	Time	Method
Percent of subjects requiring a blood transfusion (predonated blood or packed red blood cells, autologous or allogenic) anytime in the intra-operative or post-operative period (up to the earlier of Day 7 or discharge)	intra-op tp discharge

Secondary Outcome Measures

Name	Time	Method
Changes in blood markers related to inflammation and blood coagulation	surgery to discharge
The percent of subjects receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge.	surgery to discharge
The percent of subjects who did and did not predonate blood receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge.	surgery to discharge
The number of units of blood or packed red cells transfused. There will be analyses for the combination of autologous and allogenic transfusion and for allogenic alone.	surgery to discharge
The number of units of blood or packed red cells transfused per patient requiring transfusion.	surgery to discharge
The estimated blood loss during surgery, drainage (in milliliters) from the operative site in the first six hours post-operatively, and total drainage until removal of drains.	surgery to discharge
The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration (obtained in the morning of postoperative Day 2, or, if transfused earlier, prior to transfusion	pre-operative through day 2
Surgeon's assessment of the degree to which bleeding obscures his/her view of the surgical field, relative to past, similar procedures.	surgery

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial